Nventa Biopharmaceuticals Corporation
| Company type | Public |
|---|---|
| TSX: NVN | |
| Industry | Biotechnology |
| Founded | 1990 (as Stressgen Biotechnologies) |
| Defunct | 2009 |
| Fate | Merged |
| Successor | Akela Pharma, Inc |
| Headquarters | San Diego, California, United States |
Key people | Gregory M. McKee |
Number of employees | 5 |
| Website | www.nventacorp.com |
Nventa Biopharmaceuticals Corporation was a Canadian-incorporated biopharmaceutical company headquartered in San Diego, California developing therapeutics for the treatment of viral infections and cancer, focusing on diseases caused by human papillomavirus (HPV). Nventa is currently the only company applying heat shock protein (Hsp) technology to target the over 20 million Americans already infected with HPV. Previously headquartered in Victoria, British Columbia, Canada, the company’s common stock traded on the Toronto Stock Exchange under the symbol: NVN.